EGFR mutation subtype, No. (%)
|
Exon 19 deletion
|
52 (76.5)
|
0.265
|
2.27 (0.47–11.01), 0.309a
|
64 (94.1)
|
0.263
|
2.72 (0.41–18.24), 0.302a
|
Exon 21 L858R point mutation
|
6 (54.5)
| |
0.40 (0.03–5.21), 0.485b
|
9 (81.8)
| |
2.28 (0.31–16.62), 0.420b
|
Rare and complex mutation
|
5 (83.3)
| | |
6 (100)
| | |
Baseline symptomatic brain metastases, No. (%)
|
No
|
49 (81.7)
|
0.014
|
4.51 (1.45–14.00), 0.009#
|
57 (95.0)
|
0.251
|
3.0 (0.55–16.38), 0.205#
|
Yes
|
14 (56.0)
| | |
22 (88.0)
| | |
ECOG performance status, No. (%)
|
0–1
|
49 (71.0)
|
0.175
|
0.27 (0.05–1.44), 0.125#
|
64 (92.8)
|
0.889
|
0.79 (0.08–8.76), 0.835#
|
2–4
|
14 (87.5)
| | |
15 (93.8)
| | |
Abnormal organ function, No. (%)
|
No
|
53 (75.7)
|
0.468
|
1.27 (0.28–5.81), 0.755#
|
64 (91.4)
|
0.585
|
0.57 (0.07–4.97), 0.616 #
|
Yes
|
10 (66.7)
| | |
15 (100)
| | |
Afatinib dose adjustment, No. (%)
|
Dose reduced
|
23 (88.5)
|
0.084
|
5.53 (1.32–23.24), 0.019c
|
25 (96.2)
|
0.729
|
3.22 (0.29–35.40), 0.339c
|
Dose increased
|
8 (80.0)
| |
2.13 (0.36–12.57), 0.404d
|
9 (90.0)
| |
1.30 (0.11–15.02), 0.835d
|
Starting dose maintained
|
32 (65.3)
| | |
45 (91.8)
| | |
Optimal afatinib dose, No. (%)
|
Less than 40 mg once daily
|
40 (78.4)
|
0.156
|
2.03 (0.59–6.94), 0.259e
|
47 (92.2)
|
0.836
|
0.88; 0.13–6.13, 0.895e
|
40 mg once daily
|
19 (63.3)
| | |
28 (29.3)
| | |
50 mg once daily
|
4 (100)f
| | |
4 (100)f
| | |